What one share of Intensity Therapeutics holds
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.
Intensity Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.82 |
|---|---|
| Cash and investments | $3.23 |
| Book value | $3.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$55.58 | — | — | — | −$110.69 |
| 2023 | — | −$34.42 | — | — | — | $24.00 |
| 2024 | — | −$29.24 | — | — | — | $4.82 |
| 2025 | — | −$8.56 | — | — | — | $4.70 |
Common questions about Intensity Therapeutics
How much does one share of Intensity Therapeutics earn?
Over the last 12 months, Intensity Therapeutics lost $4.82 for each share.
Does Intensity Therapeutics pay a dividend?
Intensity Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Intensity Therapeutics’s book value per share?
Intensity Therapeutics’s book value is $3.13 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Intensity Therapeutics have?
Each share of Intensity Therapeutics has $3.23 of cash and investments, as of June 30, 2026.
Has Intensity Therapeutics bought back shares?
Intensity Therapeutics’s share count rose about 894% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.